^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + pepinemab (VX15) (SEMA4D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
Published date:
04/05/2021
Excerpt:
This phase 1b/2, single arm study was designed to evaluate the safety, tolerability and efficacy of pepinemab in combination with avelumab in 62 patients with advanced NSCLC...ORR with the combination therapy was higher than previously reported for single agent avelumab in the PD-L1 negative / low population.
DOI:
10.1158/1078-0432.CCR-20-4792
Source:
Title:
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC
Published date:
05/27/2020
Excerpt:
It was notable that 79% of patients who experienced PR or SD were reported to have tumors with negative or low PD-L1 expression.
DOI:
10.1158/1538-7445.AM2020-CT191
Source:
Title:
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
Published date:
05/13/2020
Excerpt:
Preliminary data suggest the combination is well tolerated and shows signs of increased antitumor activity, particularly in PD-L1 negative or low tumors.
DOI:
10.1200/JCO.2020.38.15_suppl.3011
Trial ID:
